Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Foster

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Science Advances|June 13, 2025
Regulation of PIEZO1 channel force sensitivity by interblade handshakingKatie A Smith, Eulashini Chuntharpursat-Bon, Oleksandr V Povstyan, et al.
British Journal of Pharmacology|March 3, 2018
Yoda1 analogue (Dooku1) which antagonizes Yoda1-evoked activation of Piezo1 and aortic relaxationElizabeth L Evans, Kevin Cuthbertson, Naima Endesh, et al.
Neuropharmacology|July 28, 2019
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kineticsMie Fabricius Pedersen, Tomasz Marcin Wróbel, Emil Märcher-Rørsted, et al.
Journal of Thrombosis and Haemostasis : JTH|March 29, 2023
Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systemsLewis J Hardy, Dillon Bohinc, Kara L Bane, et al.
Annals of Clinical and Translational Neurology|May 14, 2022
Scientific rationale for a higher dose of nusinersenRichard S Finkel, Monique M Ryan, Samuel Ignacio Pascual Pascual, et al.
Journal of Virology|March 11, 2016
Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7Stephanie Walter, Alexander Bollenbach, Juliane Doerrbecker, et al.
The Journal of Clinical Investigation|September 16, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophyCrystal M Proud, Richard S Finkel, Julie A Parsons, et al.
Journal of Clinical Medicine|August 12, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor FunctionSally Dunaway Young, Jacqueline Montes, Allan M Glanzman, et al.
Annals of Surgery|November 16, 2017
Mortality Trends After a Voluntary Checklist-based Surgical Safety CollaborativeAlex B Haynes, Lizabeth Edmondson, Stuart R Lipsitz, et al.
Journal of Neuromuscular Diseases|July 2, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A ResultsRichard S Finkel, John W Day, Samuel Ignacio Pascual Pascual, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Science Advances|June 13, 2025
Regulation of PIEZO1 channel force sensitivity by interblade handshakingKatie A Smith, Eulashini Chuntharpursat-Bon, Oleksandr V Povstyan, et al.
British Journal of Pharmacology|March 3, 2018
Yoda1 analogue (Dooku1) which antagonizes Yoda1-evoked activation of Piezo1 and aortic relaxationElizabeth L Evans, Kevin Cuthbertson, Naima Endesh, et al.
Neuropharmacology|July 28, 2019
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kineticsMie Fabricius Pedersen, Tomasz Marcin Wróbel, Emil Märcher-Rørsted, et al.
Journal of Thrombosis and Haemostasis : JTH|March 29, 2023
Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systemsLewis J Hardy, Dillon Bohinc, Kara L Bane, et al.
Annals of Clinical and Translational Neurology|May 14, 2022
Scientific rationale for a higher dose of nusinersenRichard S Finkel, Monique M Ryan, Samuel Ignacio Pascual Pascual, et al.
Journal of Virology|March 11, 2016
Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7Stephanie Walter, Alexander Bollenbach, Juliane Doerrbecker, et al.
The Journal of Clinical Investigation|September 16, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophyCrystal M Proud, Richard S Finkel, Julie A Parsons, et al.
Journal of Clinical Medicine|August 12, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor FunctionSally Dunaway Young, Jacqueline Montes, Allan M Glanzman, et al.
Annals of Surgery|November 16, 2017
Mortality Trends After a Voluntary Checklist-based Surgical Safety CollaborativeAlex B Haynes, Lizabeth Edmondson, Stuart R Lipsitz, et al.
Journal of Neuromuscular Diseases|July 2, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A ResultsRichard S Finkel, John W Day, Samuel Ignacio Pascual Pascual, et al.
Pageof 11